Specific markers, such as elevated liver function tests, thrombocytopenia, FDA-approved ratio of soluble Fms-like tyrosine kinase 1 (s-Flt-1) over placental growth factor (PIGF) can aid in distinguishing preeclampsia from CKD progression [25, 78]. Here, FLT1 is linked to chronic kidney disease.